Biogen Discontinues Aducanumab for Alzheimer Disease : compa

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

Related Keywords

Zerbor Adobestock , George Vradenburg , Chris Viehbacher , Drug Administration , Eisai Partnered Leqembi , Alzheimer , Aducanumab , Lecanemab ,